NOS1AP (O75052) variants and mutations
NOS1AP (also known as O75052) is a human protein-coding gene encoding a carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein. It regulates neuronal nitric-oxide signaling and interacts with proteins that influence cardiac repolarization and synaptic function. Common variants near the locus are reproducibly associated with QT-interval duration, but large-effect monogenic disease from NOS1AP variants is not well established. This analysis covers 666 NOS1AP variants and mutations. Of these, 92% have computational variant effect predictions. Disease context includes nephrotic syndrome, type 22, neurodegenerative disease, and Romano-Ward syndrome. Example NOS1AP variants include P2S, P2L, and P2P.
Variant analysis overview
- Gene: NOS1AP
- Protein: O75052
- UniProt accession: O75052
- Organism: Homo sapiens
- Variants analyzed: 666
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 525 unspecified-consequence records; 69 missense variants; 61 synonymous variants; 4 frameshift variants; 4 splice-region variants; 2 in-frame deletions; 1 stop-gained variants
- Prediction scores: 611 variants have prediction scores (92% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: nephrotic syndrome, type 22, neurodegenerative disease, Romano-Ward syndrome, alcohol drinking, smoking cessation, cervical squamous cell carcinoma, immune system disorder, familial long QT syndrome, seasonal allergic rhinitis, knee fracture, heart disorder, secondary malignant neoplasm.
Protein structure and variant hotspots
- Protein features: 1 domains; 8 post-translational modification sites.
- Structural context: 274 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable NOS1AP variants
Examples include P2S, P2L, P2P, S3T, S3N, K4Q, K4R, T5A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- P2S (p.Pro2Ser), TOPMed rs1691631077, gnomAD rs1691631077, REVEL 0.42, CADD 25.20
- P2L (p.Pro2Leu), gnomAD 1-162070182-C-T, REVEL 0.37, MetaLR 0.29
- P2P (p.Pro2Pro), gnomAD 1-162070183-T-A, CADD 15.70
- S3T (p.Ser3Thr), gnomAD rs1295249593, REVEL 0.21, CADD 22.50
- S3N (p.Ser3Asn), gnomAD 1-162070185-G-A, REVEL 0.27, MetaLR 0.13
- K4Q (p.Lys4Gln), ExAC rs760497810, gnomAD rs760497810, MetaLR 0.44, MetaSVM -0.17
- K4R (p.Lys4Arg), gnomAD 1-162070188-A-G, REVEL 0.15, MetaLR 0.14
- T5A (p.Thr5Ala), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, Variant assessed as somatic; moderate impact.
- T5S (p.Thr5Ser), TOPMed rs964924717, MetaLR 0.09, MetaSVM -1.07
- T5T (p.Thr5Thr), gnomAD 1-162070192-C-A, CADD 14.80
- Y7* (p.Tyr7Ter), 1000Genomes rs567404645, TOPMed rs567404645
- Y7Y (p.Tyr7Tyr), rs567404645, gnomAD 1-162070198-C-T, CADD 14.20
- N8K (p.Asn8Lys), NCI-TCGA TCGA novel, REVEL 0.39, CADD 26.60, Variant assessed as somatic; moderate impact.
- N8T (p.Asn8Thr), NCI-TCGA TCGA novel, MetaLR 0.49, MetaSVM 0.00, Variant assessed as somatic; moderate impact.
- N8S (p.Asn8Ser), gnomAD 1-162070200-A-G, REVEL 0.37, MetaLR 0.46
- D11Y (p.Asp11Tyr), NCI-TCGA TCGA novel, MetaLR 0.59, MetaSVM 0.24, Variant assessed as somatic; moderate impact.
- D11E (p.Asp11Glu), gnomAD 1-162070210-C-A, REVEL 0.37, MetaLR 0.28
- H14N (p.His14Asn), rs1553253970, ClinGen CA343464774, ClinVar RCV000586086, Ensembl rs1553253970, AlphaMissense 0.29, MetaLR 0.16, Uncertain significance, not provided
- H14Q (p.His14Gln), gnomAD 1-162070219-C-G, REVEL 0.10, MetaLR 0.09
- H14H (p.His14His), rs201223090, gnomAD 1-162070219-C-T, CADD 14.40
- D15G (p.Asp15Gly), gnomAD rs1214877372, REVEL 0.65, CADD 32.00
- L16V (p.Leu16Val), rs1691631574, ClinGen CA343464789, ClinVar RCV004285306, TOPMed rs1691631574, AlphaMissense 0.31, MetaLR 0.01, Uncertain significance, not specified
- L16P (p.Leu16Pro), gnomAD 1-162070224-T-C, REVEL 0.13, MetaLR 0.02
- L16L (p.Leu16Leu), gnomAD 1-162070225-G-C, CADD 14.60
- R17R (p.Arg17Arg), rs1187181602, gnomAD 1-162070226-C-A, CADD 15.50
- I18T (p.Ile18Thr), NCI-TCGA TCGA novel, MetaLR 0.03, MetaSVM -1.08, Variant assessed as somatic; moderate impact.
- P19L (p.Pro19Leu), gnomAD 1-162070233-C-T, REVEL 0.29, MetaLR 0.05
- H21R (p.His21Arg), gnomAD 1-162070239-A-G, REVEL 0.22, MetaLR 0.04
- H21H (p.His21His), gnomAD 1-162070240-C-T, CADD 15.20
- H21Q (p.His21Gln), gnomAD 1-162070240-C-G, REVEL 0.12, MetaLR 0.03
- N22K (p.Asn22Lys), TOPMed rs1485371363, gnomAD rs1485371363, REVEL 0.14, CADD 26.30
- N22D (p.Asn22Asp), gnomAD 1-162070241-A-G, REVEL 0.17, MetaLR 0.04
- E23D (p.Glu23Asp), ExAC rs764140152, TOPMed rs764140152, gnomAD rs764140152, REVEL 0.11, CADD 22.90
- E23G (p.Glu23Gly), gnomAD 1-162070245-A-G, REVEL 0.25, MetaLR 0.06
- E23E (p.Glu23Glu), rs764140152, gnomAD 1-162070246-G-A, CADD 14.60
- D24G (p.Asp24Gly), Ensembl rs1691631868
- D24Y (p.Asp24Tyr), gnomAD rs1449503877, MetaLR 0.02, MetaSVM -1.04
- D24V (p.Asp24Val), gnomAD 1-162070248-A-T, REVEL 0.31, MetaLR 0.01
- A25S (p.Ala25Ser), gnomAD rs1212578730, REVEL 0.17, CADD 28.90
- A25T (p.Ala25Thr), NCI-TCGA Cosmic COSV6263, cosmic curated COSV62632, MetaLR 0.06, MetaSVM -1.11, Variant assessed as somatic; moderate impact.
- A25A (p.Ala25Ala), gnomAD 1-162070252-C-T, CADD 16.10
- Q27Q (p.Gln27Gln), rs1253044326, gnomAD 1-162070258-G-A, CADD 13.50
- H28Q (p.His28Gln), ExAC rs776274543, TOPMed rs776274543, gnomAD rs776274543, REVEL 0.18, CADD 23.80
- H28Y (p.His28Tyr), TOPMed rs1469384693, gnomAD rs1469384693, REVEL 0.14, CADD 24.40
- H28H (p.His28His), rs776274543, gnomAD 1-162070261-C-T, CADD 12.90
- G29D (p.Gly29Asp), gnomAD rs867164651
- G29S (p.Gly29Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G29V (p.Gly29Val), gnomAD rs867164651, MetaLR 0.12, MetaSVM -0.78
- G29A (p.Gly29Ala), gnomAD 1-162070261-CG-C, CADD 33.00
- G29C (p.Gly29Cys), gnomAD 1-162070262-G-T, REVEL 0.62, MetaLR 0.10
- I30V (p.Ile30Val), ExAC rs761661228, TOPMed rs761661228, gnomAD rs761661228, REVEL 0.08, CADD 22.90
- C31Y (p.Cys31Tyr), rs1691632353, ClinGen CA343464893, ClinVar RCV001193263, Ensembl rs1691632353, AlphaMissense 0.23, MetaLR 0.01, Uncertain significance, not specified
- E33G (p.Glu33Gly), gnomAD 1-162070275-A-G, REVEL 0.19, MetaLR 0.04
- E33E (p.Glu33Glu), rs1170002965, gnomAD 1-162070276-G-A, CADD 13.70
- A34V (p.Ala34Val), cosmic curated COSV62640, gnomAD rs1411966946, REVEL 0.22, CADD 26.00
- K35E (p.Lys35Glu), ExAC rs764801253, gnomAD rs764801253, MetaLR 0.12, MetaSVM -0.81
- K35N (p.Lys35Asn), gnomAD 1-162070281-A-AT, CADD 33.00
- Y36H (p.Tyr36His), gnomAD 1-162154405-T-C, REVEL 0.43, MetaLR 0.15
- Y36Y (p.Tyr36Tyr), rs369081213, gnomAD 1-162154407-C-T, CADD 11.30
- V37A (p.Val37Ala), TOPMed rs1259606971, gnomAD rs1259606971, REVEL 0.22, CADD 24.10
- V37I (p.Val37Ile), cosmic curated COSV62632, ESP rs141560292, ExAC rs141560292, TOPMed rs141560292, REVEL 0.11, CADD 17.50
- V37L (p.Val37Leu), NCI-TCGA Cosmic COSV6263, cosmic curated COSV62639, MetaLR 0.00, MetaSVM -0.97, Variant assessed as somatic; moderate impact.
- S39T (p.Ser39Thr), gnomAD 1-162154414-AG-A, CADD 33.00
- S39G (p.Ser39Gly), gnomAD 1-162154414-A-G, REVEL 0.21, MetaLR 0.08
- L40R (p.Leu40Arg), 1000Genomes rs2102095449, REVEL 0.48, CADD 29.40
- L40L (p.Leu40Leu), rs759154024, gnomAD 1-162154417-C-T, CADD 11.70
- D41V (p.Asp41Val), gnomAD rs1207434900, REVEL 0.41, CADD 30.00
- D41N (p.Asp41Asn), gnomAD 1-162154420-G-A, REVEL 0.30, MetaLR 0.09
- D41D (p.Asp41Asp), rs41431251, gnomAD 1-162154422-C-T, CADD 9.18
- V42M (p.Val42Met), rs1485553225, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, gnomAD rs1485553225, REVEL 0.35, CADD 29.10, Variant assessed as somatic; moderate impact.
- V42V (p.Val42Val), rs1649845729, gnomAD 1-162154425-G-T, CADD 9.68
- P43A (p.Pro43Ala), gnomAD 1-162154426-C-G, REVEL 0.09, MetaLR 0.04
- R44R (p.Arg44Arg), rs754410301, gnomAD 1-162154431-G-A, CADD 10.30
- R44S (p.Arg44Ser), gnomAD 1-162154431-G-T, REVEL 0.31, MetaLR 0.04
- P45L (p.Pro45Leu), TOPMed rs1649846051, MetaLR 0.11, MetaSVM -1.00
- P45P (p.Pro45Pro), gnomAD 1-162154434-C-T, CADD 9.89
- N46I (p.Asn46Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N46K (p.Asn46Lys), Ensembl rs2102095494, MetaLR 0.01, MetaSVM -0.98
- N46S (p.Asn46Ser), gnomAD rs1259949438, REVEL 0.06, CADD 20.30
- N46N (p.Asn46Asn), gnomAD 1-162154437-C-T, CADD 13.50
- S47N (p.Ser47Asn), rs757647988, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, ExAC rs757647988, REVEL 0.19, CADD 25.80, Variant assessed as somatic; moderate impact.
- R48R (p.Arg48Arg), gnomAD 1-162154443-G-A, CADD 11.70
- V49M (p.Val49Met), gnomAD 1-162154444-G-A, REVEL 0.12, MetaLR 0.02
- V49V (p.Val49Val), gnomAD 1-162154446-G-T, CADD 11.10
- E50D (p.Glu50Asp), cosmic curated COSV10820, Ensembl rs1324497317, MetaLR 0.07, MetaSVM -1.03
- E50Q (p.Glu50Gln), Ensembl rs1649846364, REVEL 0.27, CADD 27.30
- E50K (p.Glu50Lys), gnomAD 1-162154447-G-A, REVEL 0.32, MetaLR 0.14
- I51V (p.Ile51Val), rs2525041912, ClinGen CA343465041, ClinVar RCV004357827, Uncertain significance, not specified
- I51I (p.Ile51Ile), gnomAD 1-162154452-C-A, CADD 8.19
- V52M (p.Val52Met), ExAC rs779389791, TOPMed rs779389791, gnomAD rs779389791, REVEL 0.28, CADD 27.40
- A53T (p.Ala53Thr), NCI-TCGA Cosmic COSV6263, NCI-TCGA Cosmic COSV6264, cosmic curated COSV62640, REVEL 0.10, CADD 22.90, Variant assessed as somatic; moderate impact.
- A53V (p.Ala53Val), gnomAD 1-162154457-C-T, REVEL 0.12, MetaLR 0.06
- A54T (p.Ala54Thr), gnomAD rs1364494374, REVEL 0.40, CADD 28.80
- M55T (p.Met55Thr), gnomAD 1-162154463-T-C, REVEL 0.44, MetaLR 0.11
- R56C (p.Arg56Cys), Ensembl rs878883513, REVEL 0.35, CADD 28.40
- R56H (p.Arg56His), rs1001048433, NCI-TCGA Cosmic COSV6263, cosmic curated COSV62632, TOPMed rs1001048433, REVEL 0.38, CADD 29.90, Variant assessed as somatic; moderate impact.
- R56L (p.Arg56Leu), gnomAD 1-162154466-G-T, REVEL 0.47, MetaLR 0.13
- R57P (p.Arg57Pro), 1000Genomes rs543118232, ExAC rs543118232, TOPMed rs543118232, gnomAD rs543118232, MetaLR 0.11, MetaSVM -0.87
- R57Q (p.Arg57Gln), 1000Genomes rs543118232, ExAC rs543118232, TOPMed rs543118232, gnomAD rs543118232, REVEL 0.23, CADD 31.00
- R57W (p.Arg57Trp), cosmic curated COSV62632, ExAC rs530681530, gnomAD rs530681530, REVEL 0.38, CADD 26.50
- R57R (p.Arg57Arg), rs530681530, gnomAD 1-162154468-C-A, CADD 13.10
- R59Q (p.Arg59Gln), rs746991588, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, REVEL 0.16, CADD 24.60, Variant assessed as somatic; moderate impact.
- R59W (p.Arg59Trp), cosmic curated COSV10745, ExAC rs780388688, TOPMed rs780388688, gnomAD rs780388688, REVEL 0.32, CADD 29.50
- Y60C (p.Tyr60Cys), TOPMed rs1373344682, gnomAD rs1373344682, REVEL 0.28, CADD 23.90
- Y60F (p.Tyr60Phe), TOPMed rs1373344682, gnomAD rs1373344682, REVEL 0.28, CADD 23.40
- Y60H (p.Tyr60His), NCI-TCGA TCGA novel, MetaLR 0.13, MetaSVM -0.76, Variant assessed as somatic; moderate impact.
- E61E (p.Glu61Glu), rs1019123759, gnomAD 1-162287349-G-A, CADD 4.79
- K65N (p.Lys65Asn), rs748280771, ClinGen CA1215399, ClinVar RCV004488160, ExAC rs748280771, REVEL 0.28, CADD 25.40, Uncertain significance, not specified
- K65R (p.Lys65Arg), TOPMed rs1022885762, MetaLR 0.04, MetaSVM -1.11
- K65K (p.Lys65Lys), rs748280771, gnomAD 1-162287361-G-A, CADD 8.69
- N66K (p.Asn66Lys), ExAC rs769708253, gnomAD rs769708253, REVEL 0.18, CADD 22.90
- N66N (p.Asn66Asn), gnomAD 1-162287364-C-T, CADD 7.01
- K68N (p.Lys68Asn), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, MetaLR 0.14, MetaSVM -0.66, Variant assessed as somatic; moderate impact.
- K68R (p.Lys68Arg), cosmic curated COSV10527, TOPMed rs761523382, REVEL 0.27, CADD 27.20
- K68Q (p.Lys68Gln), gnomAD 1-162287368-A-C, REVEL 0.38, MetaLR 0.11
- K68K (p.Lys68Lys), rs777758245, gnomAD 1-162287370-G-A, CADD 9.84
- K70R (p.Lys70Arg), gnomAD 1-162287375-A-G, REVEL 0.13, MetaLR 0.03
- K70T (p.Lys70Thr), gnomAD 1-162287375-A-C, REVEL 0.33, MetaLR 0.06
- K71del (p.Lys71del), gnomAD 1-162287367-CAAG-, CADD 19.20
- K71K (p.Lys71Lys), rs1440926014, gnomAD 1-162287379-A-G, CADD 8.78
- K71N (p.Lys71Asn), gnomAD 1-162287379-A-C, REVEL 0.30, MetaLR 0.06
- V72A (p.Val72Ala), TOPMed rs1465900832, gnomAD rs1465900832, REVEL 0.31, CADD 26.50
- V72G (p.Val72Gly), gnomAD 1-162287381-T-G, REVEL 0.60, MetaLR 0.18
- S73N (p.Ser73Asn), gnomAD rs1328515850, REVEL 0.06, CADD 16.70
- S73I (p.Ser73Ile), gnomAD 1-162287384-G-T, REVEL 0.21, MetaLR 0.02
- S73S (p.Ser73Ser), rs1655121962, gnomAD 1-162287385-C-T, CADD 12.50
- I74F (p.Ile74Phe), rs1363633940, ClinGen CA343392331, ClinVar RCV004488161, TOPMed rs1363633940, REVEL 0.28, CADD 25.00, Uncertain significance, not specified
- M75I (p.Met75Ile), gnomAD 1-162287391-G-A, REVEL 0.07, MetaLR 0.01
- V76G (p.Val76Gly), NCI-TCGA TCGA novel, MetaLR 0.16, MetaSVM -0.62, Variant assessed as somatic; moderate impact.
- S77* (p.Ser77Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- S77S (p.Ser77Ser), rs1164400335, gnomAD 1-162287397-A-G, CADD 6.78
- V78M (p.Val78Met), gnomAD 1-162287398-G-A, REVEL 0.34, MetaLR 0.15
- V78L (p.Val78Leu), gnomAD 1-162287398-G-C, REVEL 0.24, MetaLR 0.11
- V78V (p.Val78Val), gnomAD 1-162287400-G-A, CADD 9.01
- G80V (p.Gly80Val), NCI-TCGA TCGA novel, MetaLR 0.18, MetaSVM -0.52, Variant assessed as somatic; moderate impact.
- G80A (p.Gly80Ala), gnomAD 1-162287405-G-C, REVEL 0.48, MetaLR 0.16
- G80G (p.Gly80Gly), rs1382068974, gnomAD 1-162287406-A-G, CADD 8.95
- V81G (p.Val81Gly), Ensembl rs1571191811, REVEL 0.60, CADD 28.60
- V81M (p.Val81Met), ExAC rs749016887, gnomAD rs749016887, REVEL 0.43, CADD 26.40
- V81A (p.Val81Ala), gnomAD 1-162287408-T-C, REVEL 0.44, MetaLR 0.17
- K82E (p.Lys82Glu), TOPMed rs1474301019, gnomAD rs1474301019, REVEL 0.45, CADD 26.90
- K82N (p.Lys82Asn), gnomAD 1-162287412-A-C, REVEL 0.26, MetaLR 0.08
- V83M (p.Val83Met), NCI-TCGA TCGA novel, MetaLR 0.12, MetaSVM -0.84, Variant assessed as somatic; moderate impact.
- V83V (p.Val83Val), gnomAD 1-162287415-G-T, CADD 6.38
- I84T (p.Ile84Thr), ExAC rs770775573, TOPMed rs770775573, gnomAD rs770775573, REVEL 0.10, CADD 22.00
- K86Q (p.Lys86Gln), TOPMed rs1419039197, gnomAD rs1419039197, REVEL 0.07, CADD 22.40
- K86K (p.Lys86Lys), gnomAD 1-162287424-G-A, CADD 10.60
- K87N (p.Lys87Asn), NCI-TCGA TCGA novel, MetaLR 0.10, MetaSVM -0.99, Variant assessed as somatic; moderate impact.
- K87E (p.Lys87Glu), gnomAD 1-162287425-A-G, REVEL 0.39, MetaLR 0.09
- K88E (p.Lys88Glu), TOPMed rs1655123209, REVEL 0.28, CADD 28.90
- K88K (p.Lys88Lys), gnomAD 1-162287430-G-A, CADD 10.10
- K89* (p.Lys89Ter), ExAC rs773827552, gnomAD rs773827552, CADD 39.00
- K89N (p.Lys89Asn), Ensembl rs1655123336, MetaLR 0.08, MetaSVM -0.99
- K90E (p.Lys90Glu), rs1215631561, ClinGen CA343392604, ClinVar RCV000623880, TOPMed rs1215631561, AlphaMissense 0.75, MetaLR 0.06, Uncertain significance, not specified
- K90Q (p.Lys90Gln), TOPMed rs1215631561, gnomAD rs1215631561, REVEL 0.16, AlphaMissense 0.75, Uncertain significance
- K90S (p.Lys90Ser), NCI-TCGA TCGA novel, MetaLR 0.03, MetaSVM -1.06, Variant assessed as somatic; high impact.
- K90del (p.Lys90del), rs530021849, gnomAD 1-162287420-TGAA-, CADD 19.80
- K90R (p.Lys90Arg), gnomAD 1-162287435-A-G, REVEL 0.08, MetaLR 0.03
- K90K (p.Lys90Lys), rs1248977194, gnomAD 1-162287436-G-A, CADD 22.80
- L91F (p.Leu91Phe), TOPMed rs1261184608, gnomAD rs1261184608, REVEL 0.04, CADD 18.20
- L91I (p.Leu91Ile), TOPMed rs1261184608, gnomAD rs1261184608, REVEL 0.02, CADD 16.60
- L91R (p.Leu91Arg), NCI-TCGA Cosmic COSV6263, MetaLR 0.01, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- L91S (p.Leu91Ser), gnomAD 1-162287430-G-GAA, CADD 32.00
- L92F (p.Leu92Phe), TOPMed rs1442779059, gnomAD rs1442779059, REVEL 0.14, CADD 22.30
- L92H (p.Leu92His), rs1486725581, ClinGen CA343395128, ClinVar RCV004324632, TOPMed rs1486725581, REVEL 0.23, CADD 24.00, Uncertain significance, not specified
- L92I (p.Leu92Ile), NCI-TCGA Cosmic COSV6263, MetaLR 0.03, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- L93V (p.Leu93Val), NCI-TCGA TCGA novel, REVEL 0.10, CADD 22.70, Variant assessed as somatic; moderate impact.
- L93L (p.Leu93Leu), gnomAD 1-162300639-T-C, CADD 9.05
- L94M (p.Leu94Met), ExAC rs771750757, gnomAD rs771750757, REVEL 0.11, CADD 25.20
- K97R (p.Lys97Arg), NCI-TCGA TCGA novel, MetaLR 0.09, MetaSVM -0.97, Variant assessed as somatic; high impact.
- K97K (p.Lys97Lys), rs775284971, gnomAD 1-162300653-G-A, CADD 8.99
- E98K (p.Glu98Lys), NCI-TCGA Cosmic COSV6263, cosmic curated COSV62635, REVEL 0.17, CADD 23.10, Variant assessed as somatic; moderate impact.
- E98E (p.Glu98Glu), gnomAD 1-162300656-A-G, CADD 8.87
- W99G (p.Trp99Gly), TOPMed rs1028428519, REVEL 0.40, CADD 25.50
- W99R (p.Trp99Arg), TOPMed rs1028428519, MetaLR 0.46, MetaSVM 0.04
- W99C (p.Trp99Cys), gnomAD 1-162300659-G-T, REVEL 0.39, MetaLR 0.57
- W99* (p.Trp99Ter), gnomAD 1-162300659-G-A, CADD 39.00
- T100M (p.Thr100Met), rs201591597, cosmic curated COSV10527, TOPMed rs201591597, gnomAD rs201591597, REVEL 0.19, CADD 23.40, Variant assessed as somatic; moderate impact.
- T100T (p.Thr100Thr), rs578153577, gnomAD 1-162300662-G-A, CADD 0.37
- W101* (p.Trp101Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
Public NOS1AP analysis runs
- NOS1AP analysis run — NOS1AP (666 variants) — completed 2026-08-20